The changing dimensions of rheumatoid arthritis and its treatment.

631 Editorials Bulletin of the World Health Organization 2003, 81 (9) Unlike degenerative processes, rheuma- toid arthritis begins within the synovi- um, the lining of diarthrodial (move- able) joints. The initial reaction appears to be a cellular immune response directed against an unknown antigen or antigens in a genetically predisposed host. The activation of helper T-lymphocytes leads to release of inflammatory cytokines by these cells, and attraction of macrophages into the synovium and of polymor- phonuclear leukocytes into the syn- ovial fluid. The synovial lining cells proliferate in numbers and state of activation. The proliferative “pannus” behaves as a locally invasive malignan- cy, burrowing into and destroying arti- cular cartilage and subchondral bone. For many years physicians have known that prolonged administration of glucocorticoids in high doses pro- duce diabetes mellitus, cataracts, fragile skin, osteoporosis and hypertension in patients, and that the standard non- steroidal anti-inflammatory drugs initi- ate duodenal ulcers and bleeding. Disease-modifying agents such as gold salts were used with good results, but with their own side-effects. In the late 1970s numerous groups demonstrated that methotrexate, used in low doses each week, was very useful and minimal- ly toxic for rheumatoid arthritis. This drug, in a sense, “turned the corner” for therapy in rheumatoid arthritis. Since then there have been two further advances: the production and successful use of targeted therapy against inflammatory cytokines, and the discovery that the prevalence of rheumatoid arthritis is lower than the “1% of the population” previously thought. We now know that the inci- dence of rheumatoid arthritis is decreasing. For example, its incidence in Rochester, Minnesota, declined by 50% between 1950 and 1974 (1), and in the same group the age- and sex- adjusted incidence per 100 000 popu- lation fell from 62 in the decade of 1955–64 to 33 in that of 1985–94 (2). Throughout these decades there have been cyclical patterns, suggesting the influence of environmental factors. In addition, seropositivity for rheumatoid factor is decreasing; the highest likeli- hood of seropositivity was in those born at the turn of the 20th century. Along with the decline in incidence, and a shift towards an older age at onset of rheumatoid arthritis, these data suggest a birth-cohort effect, very likely from something infectious (3). Rheumatologists are getting bet- ter at predicting the course of the con- dition as well as diagnosing it more accurately. A valuable prediction model for persistent erosive rheuma- toid arthritis has been developed in Europe. It consists of seven variables according to which the physician can put a patient at the time of diagnosis into one of three probable outcome cohorts: self-limiting arthritis; persist- ent but non-erosive arthritis; and per- sistent erosive arthritis (4). The vari- ables are: symptom duration at first visit; morning stiffness for more than one hour; arthritis in three or more joints; bilateral metatarsophalangeal joint compression pain; rheumatoid factor positivity; anti-citrullinated peptide antibody positivity; and radi- ographic erosions. These variables are very similar to those that comprise the American College of Rheumatology Criteria for Classification of Rheumatoid Arthritis. The corresponding weighting system gives the prognostic capacity (4). The unusual addition to the other factors is the anti-citrullinated peptide anti- body. A high percentage of patients with rheumatoid arthritis have sub- stantial titres of antibody to peptides containing citrulline, and citrullinated peptides are found in rheumatoid syn- ovium. As of 2003 it has equal weight with rheumatoid factor for predicting destructive disease. Despite the improved predictions for course, current data suggest that when good physician care is available, medical care costs for rheumatoid arthritis exceed US$ 6000 a year per patient (5). Recent trends suggest that this will go down, however. In addition to drugs, effective chronic disease management includes patients taking a strong interest in and responsibility for their care. The use of allied health personnel to work in small groups with patients who exchange information, complaints, tips on activi- ties of daily living, and sensible exercise, can save visits to physicians as well as to emergency facilities. Part and parcel of better care for rheumatoid patients must be improved education for future physicians. The Bone and Joint Decade International Steering Committee is working hard to increase the quality and quantity of curricula in muscu- loskeletal medicine in medical schools. As rheumatologists, orthopaedists and general practitioners, we must cap- italize on clinical science to develop better therapy, and use cost-effective techniques of physician and allied health personnel to manage patients in all countries of the world. ■ 1. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1966-1985. Arthritis and Rheumatism 1999;42:415-20. 2. Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis and Rheumatism 2002;46:625-31. 3. Enzer I, Dunn G, Jacobsson L. An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians. Arthritis and Rheumatism 2002;46:1729-34. 4. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism 2002;46:357-65. 5. Yelin E and Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis and Rheumatism 1999;42: 1209-18. 6. Genovese MC, Harris ED Jr. Treatment of Rheumatoid Arthritis. In: Harris ED Jr, Ruddy S, Budd R, Sergent J, Genovese MC, Firestein G, editors. Textbook of rheumatology, 7th ed. Philadelphia: WB Saunders. Forthcoming 2004. 1 George DeForest Barnett Professor of Medicine Emeritus, Stanford University, Alpha Omega Alpha, Ste.130 525 Middlefield Rd. Menlo Park, CA 94025, USA (email: e.harris@alphaomegaalpha.org). The changing dimensions of rheumatoid arthritis and its treatment Edward D. Harris, Jr.1